The PREVENT trial was a one year, phase III study that showed significant benefits when secukinumab (SEC) was given to patients with active non‐radiographic axial spondyloarthritis (nr‐axSpA) for 52 weeks.
To be enrolled patients had to have inflammatory low back pain and have either
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
A case-controlled study shows that methotrexate (MTX) use in rheumatoid arthritis (RA) is not associated with interstitial lung disease (ILD) according to a report in the European Respiratory Journal.
Researchers examined the associatioin by comparing 410 RA patients with
Read Article
The interleukin (IL)-1β inhibitor canakinumab (Ilaris) showed promise for preventing the need for hip or knee replacement among patients with osteoarthritis in an exploratory analysis of data from a randomized clinical trial, investigators reported.
Among patients enrolled in CANTOS, the pooled
Does repeat bone mineral density (BMD) measurement predict subsequent fracture risk in postmenopausal women? A study published in JAMA suggests that a second BMD done 3 years after the initial DEXA did not further distinguish women who would be at a higher risk for a future hip fracture or
Read Article
Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
Yesterday the FDA approved secukinumab (Cosentyx) for the treatment of patients with active non-radiographic axial spondyloarthritis (nr-axSpA). There are now three agents that are FDA approved for nr-axSpA: certolizumab, ixekizumab and now, secukinumab.
Read Article
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Read Article
Olga Petryna DrPetryna ( View Tweet)
Olga Petryna DrPetryna ( View Tweet)
Olga Petryna DrPetryna ( View Tweet)
Links:
Links:
Links:
Links:
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Today Eli Lilly announced that Taltz (ixekizumab) has received FDA approval for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Ixekizumab (an IL-17A inhibitor) would join certolizumab (TNF inhibitor) as the only 2 drugs approved by the FDA for nr-
Read Article
Nagaraja, Khanna and colleagues have published an overview of current and future therapies in patients with systemic sclerosis (SSc) and have reviewed the potential outcome measures for this difficult autoimmune disorder. Notably there have been several novel agents studied in recent years,
Read Article
JAMA Internal Medicine has reported that cigarette smoking associated with an increased odds of having antineutrophil cytoplasmic antibody–associated vasculitis (AAV) (especially MPO positive AAV) and is thereby a modifiable risk factor for AAV.
In a case-control study, 473 AAV
Read Article
